Research Papers

25 of 530 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
A deep learning based holistic diagnosis system for immunohistochemistry interpretation and molecular subtyping.
Fan L; Liu J; Ju B; Lou D; Tian Y.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selectio…
Jiang MQ; Qian LQ; Shen YJ; Fu YY; Feng W; Ding ZP; Han YC; Fu XL.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Tumor microenvironment(TME) and single-source dual-energy CT(ssDECT) on assessment of inconformity between RECIST1.1 an…
Sun C; Ma X; Meng F; Chen X; Wang X; Sun W; Xu Y; He H; Zhang H; Ma K.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
High-throughput sequencing and in-silico analysis confirm pathogenicity of novel MSH3 variants in African American colo…
Rashid M; Rashid R; Gadewal N; Carethers JM; Koi M; Brim H; Ashktorab H.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS-STING pathway activation.
Wu Y; Lin Y; Shen F; Huang R; Zhang Z; Zhou M; Fang Y; Shen J; Fan X.
Neoplasia (Unknown)
Published: 2024
4/6 Transparent
Data Funding Declared
DNA methylation landscape reveals GNAS as a decitabine-responsive marker in patients with acute myeloid leukemia.
He S; Li Y; Wang L; Li Y; Xu L; Cai D; Zhou J; Yu L.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Tozasertib activates anti-tumor immunity through decreasing regulatory T cells in melanoma.
Wang Q; Liu W; Zhou H; Lai W; Hu C; Dai Y; Li G; Zhang R; Zhao Y.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of res…
Hecht M; Frey B; Gaipl US; Tianyu X; Eckstein M; Donaubauer AJ; Klautke G; Illmer T; Fleischmann M; Laban S; Hautmann MG; Tamaskovics B; Brunner TB; Becker I; Zhou JG; Hartmann A; Fietkau R; Iro H; Döllinger M; Gostian AO; Kist AM.
Neoplasia (Unknown)
Published: 2024
4/6 Transparent
Data Registered
RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells.
Lv F; Si W; Xu X; He X; Wang Y; Li Y; Li F.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Hsa_circ_0001583 fuels bladder cancer metastasis by promoting staphylococcal nuclease and tudor domain containing 1-med…
Liu C; Cong Y; Chen L; Lv F; Cheng L; Song Y; Xing Y.
Neoplasia (Unknown)
Published: 2024
3/6 Transparent
Funding Declared
Secreted insulin-like growth factor binding protein 5 functions as a tumor suppressor and chemosensitizer through inhib…
Zhang B; Deng X; You R; Liu J; Hou D; Wang X; Chen S; Li D; Fu Q; Zhang J; Huang H; Chen X.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Characteristics and survival of primary urothelial carcinoma of the prostate: A multi-center retrospective study of 18 …
Ji J; Liu T; Yao Y; Liu W; Ning H; Wang T; Zhang G.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Advanced progress of spatial metabolomics in head and neck cancer research.
Zhao H; Shi C; Han W; Luo G; Huang Y; Fu Y; Lu W; Hu Q; Shang Z; Yang X.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Immune infiltration, aggressive pathology, and poor survival outcomes in RECQL helicase deficient breast cancers.
Lashen A; Al-Kawaz A; Jeyapalan JN; Alqahtani S; Shoqafi A; Algethami M; Toss M; Green AR; Mongan NP; Sharma S; Akbari MR; Rakha EA; Madhusudan S.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma.
Afaq F; Agarwal S; Bajpai P; Diffalha SA; Kim HG; Peter S; Khushman M; Chauhan SC; Mukherjee P; Varambally S; Manne U.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combina…
Winter M; Nait Eldjoudi A; Guette C; Hondermarck H; Bourette RP; Fovez Q; Laine W; Ghesquiere B; Adriaenssens E; Kluza J; Le Bourhis X.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system.
Miller CP; Fung M; Jaeger-Ruckstuhl CA; Xu Y; Warren EH; Akilesh S; Tykodi SS.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Acral melanoma: new insights into the immune and genomic landscape.
Carvalho LAD; Aguiar FC; Smalley KSM; Possik PA.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Time-restricted feeding affects the fecal microbiome metabolome and its diurnal oscillations in lung cancer mice.
Fang G; Wang S; Chen Q; Luo H; Lian X; Shi D.
Neoplasia (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Integration of bioinformatics and machine learning strategies identifies APM-related gene signatures to predict clinica…
Shen HY; Xu JL; Zhu Z; Xu HP; Liang MX; Xu D; Chen WQ; Tang JH; Fang Z; Zhang J.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting IL-23 for the interception of obesity-associated colorectal cancer.
Madka V; Chiliveru S; Panneerselvam J; Pathuri G; Zhang Y; Stratton N; Kumar N; Sanghera DK; Rao CV.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcino…
Tuna M; Mills GB; Amos CI.
Neoplasia (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
ΔNp63 silencing, DNA methylation shifts, and epithelial-mesenchymal transition resulted from TAp63 genome editing in sq…
Katoh I; Tsukinoki K; Hata RI; Kurata SI.
Neoplasia (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study.
Bon G; Krasniqi E; Porru M; D'Ambrosio L; Scalera S; Maugeri-Saccà M; Di Lisa FS; Filomeno L; Arcuri T; Botticelli A; Santini D; Fabbri MA; D'Auria G; Pulito C; Blandino G; Marchiò C; Barba M; Ciliberto G; Vici P; Pizzuti L.
Neoplasia (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-gr…
Hoffmann I; Dragomir MP; Monjé N; Keunecke C; Kunze CA; Schallenberg S; Marchenko S; Schmitt WD; Kulbe H; Sehouli J; Braicu IE; Jank P; Denkert C; Darb-Esfahani S; Horst D; Sinn BV; Sers C; Bischoff P; Taube ET.
Neoplasia (Unknown)
Published: 2023
4/6 Transparent
Code Funding Declared